

## SPINE SAFETY CAUTIONARY NOTICE:

### **Information for Healthcare Professionals: Prilosec (omeprazole) Delayed-Release Capsules, Prilosec (omeprazole magnesium) For Delayed Release Oral Suspension: Labeling Changes**

According to MedWatch, FDA notified healthcare professionals of labeling changes for Prilosec (omeprazole) Delayed-Release Capsules, Prilosec (omeprazole magnesium) For Delayed Release Oral Suspension. The following has been added to the labeling:

## **WARNINGS AND PRECAUTIONS**

### ***Concomitant use of Prilosec with St John's Wort or rifampin***

- Drugs which induce CYP2C19 or CYP3A4 (such as St John's Wort or rifampin) can substantially decrease omeprazole concentrations. Avoid concomitant use of Prilosec with St John's Wort or rifampin. Warning and Precautions (5) section with information regarding interactions with diagnostic investigations for neuroendocrine tumors, and concomitant use with St. John's Wort or rifampin.

### ***Interactions with Investigations for Neuroendocrine Tumors***

- Serum chromogranin A (CgA) levels increase secondary to drug induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop omeprazole treatment before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.

## **DRUG INTERACTIONS**

- with information regarding interactions with diagnostic investigations for neuroendocrine tumors, and concomitant use with tacrolimus, digoxin, St. John's Wort or rifampin, and clopidogrel.

## **PATIENT PACKAGE INSERT**

### ***Tell your doctor about all of the medicines you take***

- addition of St. John's Wort (*Hypericum perforatum*) and Rifampin to the medication list

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members.

Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.